Incyte Corporation has announced promising results for ruxolitinib in the Novartis-sponsored Phase III...
- Positive results for ruxolitinib in graft-versus-host disease
- Mundipharma demonstrates superiority of non-opioid Penthrox in relieving pain
- Pfizer’s JAK1 inhibitor performs well in atopic dermatitis
- From injections to pills: FDA approves first oral GLP-1 for type 2 diabetes
- Keytruda approved in China as a monotherapy for NSCLC
Positive results for ruxolitinib in graft-versus-host disease
Incyte Corporation has announced promising results for ruxolitinib in the Novartis-sponsored Phase III trial REACH2 of patients with steroid-refractory acute graft-versus-host disease.
Aqueous Cleaning in Pharmaceutical Manufacturing
The use of aqueous cleaning in pharmaceutical manufacturing can provide numerous benefits in terms of effectiveness, minimal surface residue, and easier cleaning validation.
Mundipharma demonstrates superiority of non-opioid Penthrox in relieving pain
At the European Society of Emergency Medicine Congress, UK-based Mundipharma announced positive results from various trials of its analgesic Penthrox (methoxyflurane) for pain relief.
Defining Ideal Modular Design for Effective Pharmaceutical Packaging
The essence of modular design is to create an overall architecture where a complex product or system is broken down into discrete component modules or ‘skids’ that perform specific roles and that can be integrated at will into the overall structure.
Pfizer’s JAK1 inhibitor performs well in atopic dermatitis
Pfizer has announced promising results from its Phase III JADE MONO-1 study of janus kinase 1 (JAK1) inhibitor abrocitinib in atopic dermatitis.
From injections to pills: FDA approves first oral GLP-1 for type 2 diabetes
Almost 15 years after the approval of the first GLP-1 agonist, the US FDA has approved the first oral version of this treatment approach for type 2 diabetes. What are the benefits of a pill-based, rather than injectable version, of GLP-1 analogues for this patient population?
Industry 4.0: Revolutionising Life Science Manufacturing Through Connected Systems
The life science industry has a strong legacy in data collection and has been embracing Industry 4.0 methodology before the term existed.
ASTM International to Hold Board Meeting and Related Events in Boston
On 13-16 October in Boston, Massachusetts, US, ASTM International, a world-leading standards developer, will hold its board meeting and related events.
Keytruda approved in China as a monotherapy for NSCLC
Merck has announced that Keytruda has been approved by the Chinese National Medical Products Administration (NMPA) as a monotherapy for first-line treatment of local advanced or metastatic non-small cell lung cancer (NSCLC).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.